HUTCHMED (China) Limited (HKG:0013)
Hong Kong · Delayed Price · Currency is HKD 23.26
+0.08 (0.35%)
At close: Feb 13, 2026
HUTCHMED (China) Employees
HUTCHMED (China) had 1,780 employees as of June 30, 2025.
Employees
1,780
Change
n/a
Growth
n/a
Revenue / Employee
2.66M HKD
Profits / Employee
2.06M HKD
Market Cap
19.69B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 1,780 | - | - |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| China Resources Pharmaceutical Group | 86,000 |
| The United Laboratories International Holdings | 17,400 |
| Grand Pharmaceutical Group | 12,440 |
| Simcere Pharmaceutical Group | 6,815 |
| Sunshine Lake Pharma | 4,861 |
| Consun Pharmaceutical Group | 3,073 |
| Sihuan Pharmaceutical Holdings Group | 2,767 |
| CanSino Biologics | 1,115 |
HUTCHMED (China) News
- 8 days ago - HUTCHMED to Announce 2025 Final Results - GlobeNewsWire
- 11 days ago - HUTCHMED (China) Ltd (HCM) Stock Price Down 3.53% on Feb 2 - GuruFocus
- 4 weeks ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 5 weeks ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 5 weeks ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 5 weeks ago - HUTCHMED's ESLIM-02 Trial Of Sovleplenib In Warm Autoimmune Hemolytic Anemia Meets Key Goal - Nasdaq
- 5 weeks ago - HUTCHMED's Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China - Nasdaq
- 5 weeks ago - HCM's Sovleplenib Trial Achieves Key Milestone in Treating Autoimmune Hemolytic Anemia - GuruFocus